Filters

Pp-145 manufacturers

Filters

None products found

pp-145

Solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: BCG-unresponsive NMIBC (FDA approved with BCG, 2024); Phase 3 expansion: NSCLC, colorectal, head and neck Clinical stage: Approved (NMIBC) + Phase 3 solid tumour expansion Modality: Biologic (IL-15/IL-15Rα-Fc fusion superagonist complex) Mechanism / Target: IL-15 superagonist — activates NK cells and CD8+ memory T cells without Treg expansion; trans-presents IL-15 via IL-15Rα for superior potency vs IL-15 monomer Route / form: Intravesical instillation (bladder); intravenous infusion (systemic tumours) Differentiation: First-approved IL-15 agent; avoids Treg-stimulating IL-2 effects; broad combinability with checkpoint inhibitors; proven activity in bladder cancer with intravesical delivery
Manufacturer #39176

Commercial-stage immuno-oncology company with an FDA-approved IL-15 superagonist. Expands approved asset into multiple solid tumour indications with wholly owned Phase 3 studies. Integrated manufacturing and commercialisation infrastructure in oncology.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.